CA2726136C - Stabilized transdermal drug delivery system - Google Patents

Stabilized transdermal drug delivery system Download PDF

Info

Publication number
CA2726136C
CA2726136C CA2726136A CA2726136A CA2726136C CA 2726136 C CA2726136 C CA 2726136C CA 2726136 A CA2726136 A CA 2726136A CA 2726136 A CA2726136 A CA 2726136A CA 2726136 C CA2726136 C CA 2726136C
Authority
CA
Canada
Prior art keywords
adhesive
therapeutic agent
solution
release liner
drug delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2726136A
Other languages
English (en)
French (fr)
Other versions
CA2726136A1 (en
Inventor
Jiashang Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mylan Inc
Original Assignee
Mylan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41380695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2726136(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mylan Inc filed Critical Mylan Inc
Publication of CA2726136A1 publication Critical patent/CA2726136A1/en
Application granted granted Critical
Publication of CA2726136C publication Critical patent/CA2726136C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T156/00—Adhesive bonding and miscellaneous chemical manufacture
    • Y10T156/10—Methods of surface bonding and/or assembly therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2726136A 2008-05-30 2009-05-29 Stabilized transdermal drug delivery system Active CA2726136C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5745508P 2008-05-30 2008-05-30
US61/057,455 2008-05-30
PCT/US2009/045739 WO2009158120A2 (en) 2008-05-30 2009-05-29 Stabilized transdermal drug delivery system

Publications (2)

Publication Number Publication Date
CA2726136A1 CA2726136A1 (en) 2009-12-30
CA2726136C true CA2726136C (en) 2016-11-01

Family

ID=41380695

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2726136A Active CA2726136C (en) 2008-05-30 2009-05-29 Stabilized transdermal drug delivery system

Country Status (11)

Country Link
US (2) US20110182949A1 (OSRAM)
EP (1) EP2299989B1 (OSRAM)
JP (2) JP5695562B2 (OSRAM)
KR (1) KR101590209B1 (OSRAM)
CN (1) CN102099020B (OSRAM)
AU (2) AU2009262871B2 (OSRAM)
BR (1) BRPI0913214B1 (OSRAM)
CA (1) CA2726136C (OSRAM)
MX (1) MX2010012989A (OSRAM)
NZ (1) NZ589542A (OSRAM)
WO (1) WO2009158120A2 (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010012989A (es) * 2008-05-30 2011-04-27 Mylan Inc Sistema de suministro de farmaco transdermico estabilizado.
WO2011034323A2 (en) * 2009-09-16 2011-03-24 Samyang Corporation Transdermal delivery system, method for manufacturing the same, and transdermal delivery method using the system
HRP20181173T1 (hr) 2009-12-22 2018-09-21 Ucb Biopharma Sprl Polivinilpirolidon za stabilizaciju čvrste disperzije nekristalnog oblika rotigotina
CN104582693A (zh) * 2012-08-15 2015-04-29 道康宁公司 多层药物递送系统
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
JP2016135744A (ja) * 2013-05-08 2016-07-28 株式会社 ケイ・エム トランスダーム 貼付剤
CA2916183C (en) 2013-07-03 2022-03-29 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system with electronic component
JP6359014B2 (ja) * 2013-08-21 2018-07-18 久光製薬株式会社 貼付剤
PL3096746T3 (pl) * 2014-01-22 2019-09-30 4P Therapeutics Systemy transdermalne zapobiegające nadużywaniu i niewłaściwemu użyciu
JP6573913B2 (ja) * 2014-05-20 2019-09-11 エルテーエス ローマン テラピー−ジステーメ アーゲー ロチゴチンを含む経皮送達システム
JP6895755B2 (ja) 2014-05-20 2021-06-30 エルテーエス ローマン テラピー−ジステーメ アーゲー 経皮送達システムにおける活性薬剤の放出を調節するための方法
EP4238580A3 (en) * 2014-05-20 2023-10-25 LTS Lohmann Therapie-Systeme AG Transdermal delivery system including an interface mediator
WO2016049266A1 (en) * 2014-09-24 2016-03-31 Pain Therapeutics, Inc. 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal
US10010543B1 (en) 2014-12-23 2018-07-03 Barr Laboratories, Inc. Transdermal dosage form
US9650338B1 (en) 2016-07-29 2017-05-16 VDM Biochemicals, Inc. Opioid antagonist compounds and methods of making and using
ES3001152T3 (es) 2016-12-20 2025-03-04 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polisiloxano o poliisobutileno
PL3338768T3 (pl) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
KR102241892B1 (ko) 2017-01-25 2021-04-20 한국전자기술연구원 백스캐터 통신을 위한 데이터 부호화 방법 및 이를 위한 장치
US11179469B2 (en) 2017-04-28 2021-11-23 Nitto Denko Corporation Transdermal absorption preparation
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
EP3810099A1 (en) 2018-06-20 2021-04-28 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine
US20220117934A1 (en) * 2019-02-15 2022-04-21 Hisamitsu Pharmaceutical Co., Inc. Rotigotine stabilization method
CN113677343B (zh) * 2019-03-19 2023-11-24 耐贝医药株式会社 生物体对药物的吸收性优异且化学稳定性也优异的医药组合物
WO2020243506A1 (en) * 2019-05-31 2020-12-03 Kindeva Drug Delivery Removable film-forming gel compositions featuring adhesion promoters
PL3854388T3 (pl) 2020-01-24 2024-02-26 Luye Pharma Switzerland Ag Transdermalny system terapeutyczny z substancją czynną rotygotyną i co najmniej jednym klejem silikonowym nieodpornym na działanie amin
JP7716111B2 (ja) * 2020-08-31 2025-07-31 ノーベルファーマ株式会社 神経変性疾患の症状の緩和又は治療のための貼付剤
CN112891324A (zh) * 2021-01-19 2021-06-04 北京亚宝生物药业有限公司 一种透皮贴剂
KR102363479B1 (ko) * 2021-03-12 2022-02-15 환인제약 주식회사 로티고틴 함유 경피 흡수 제제
JP2024520271A (ja) * 2021-06-06 2024-05-24 スタートン セラピューティクス インコーポレイテッド 治療上有効な量のレナリドミドまたは他の免疫調節剤を投与するための経皮薬物送達システム
CN113648297B (zh) * 2021-08-16 2023-07-14 乐明药业(苏州)有限公司 一种含有氟比洛芬的药物组合物与贴剂
WO2024144130A1 (ko) * 2022-12-26 2024-07-04 환인제약 주식회사 경피흡수용 제제 및 이의 제조 방법

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2920500A1 (de) * 1979-05-21 1980-11-27 Boehringer Sohn Ingelheim Pharmazeutische zubereitung in form eines polyacrylatfilmes
DE3204551A1 (de) 1982-02-10 1983-08-18 Boehringer Ingelheim KG, 6507 Ingelheim Verfahren zur herstellung einer pharmazeutischen zubereitung in form eines polyacrylat-films
JPS60169414A (ja) * 1984-02-14 1985-09-02 Taisho Pharmaceut Co Ltd 経皮吸収剤
US4880633A (en) * 1986-03-12 1989-11-14 Merck & Co., Inc. Transdermal drug delivery system
US4797284A (en) 1986-03-12 1989-01-10 Merck & Co., Inc. Transdermal drug delivery system
US4832953A (en) 1987-08-13 1989-05-23 Alza Corporation Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
GB9021674D0 (en) 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
US5164190A (en) 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
IT1253265B (it) * 1991-11-25 1995-07-14 Rotta Research Lab Preparato a matrice copolimerica adesiva a base acrilica per il rilascio transdermico dell'estradiolo.
US5494680A (en) * 1993-12-08 1996-02-27 Minnesota Mining And Manufacturing Company Transdermal delivery device
AU702593B2 (en) 1994-09-14 1999-02-25 Minnesota Mining And Manufacturing Company Matrix for transdermal drug delivery
US5662928A (en) * 1995-04-21 1997-09-02 Ciba-Geigy Corporation Method for the prevention or removal of crystalline scopolamine in a non-aqueous matrix of a transdermal system
KR970009795A (ko) * 1995-08-30 1997-03-27 이웅열 경피투여용 첩부제 조성물
US5906830A (en) * 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
DE69616370T2 (de) 1995-12-01 2002-07-11 Alza Corp., Palo Alto Verbessertes verfahren zur verhinderung der kristallbildung in einer dispersion eines flüssigen stoffes in einer matrix
US6238700B1 (en) * 1995-12-01 2001-05-29 Alza Corporation Method for preventing crystal formation in a dispersion of a liquid in a matrix
DE19548332A1 (de) 1995-12-22 1997-07-10 Rotta Res Bv Hormonpflaster
US6623763B2 (en) 1996-01-08 2003-09-23 Lts Lohmann Therape-System Ag Pharmaceutical preparation adhering to the skin, in particular a transdermal therapeutic system for the release of 17-β-estradiol to the human organism
US5869089A (en) 1996-03-21 1999-02-09 China-America Technology Corp. (Ctc) Manufacturing method of programmable transdermal therapeutic system
DE19629468A1 (de) * 1996-07-11 1998-01-15 Schering Ag Transdermale therapeutische Systeme
US20040018241A1 (en) * 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
DE19906152B4 (de) * 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
DE10060550C1 (de) 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
US8496960B2 (en) 2001-10-23 2013-07-30 Purdue Pharma L.P. Terazosin transdermal device and methods
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
WO2005123046A1 (en) * 2004-06-15 2005-12-29 Amorepacific Corporation Novel transdermal preparation and its producing method
DE102004062182B4 (de) * 2004-12-20 2007-06-06 Bayer Schering Pharma Ag Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff
US20060188558A1 (en) * 2005-02-18 2006-08-24 Mylan Technologies, Inc. Transdermal systems having control delivery system
WO2007077741A1 (ja) 2005-12-28 2007-07-12 Hisamitsu Pharmaceutical Co., Inc. 経皮吸収型製剤
US20080226698A1 (en) * 2007-03-16 2008-09-18 Mylan Technologies, Inc. Amorphous drug transdermal systems, manufacturing methods, and stabilization
US8426439B2 (en) * 2007-04-11 2013-04-23 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
MX2010012989A (es) * 2008-05-30 2011-04-27 Mylan Inc Sistema de suministro de farmaco transdermico estabilizado.
EP2675434A1 (en) 2011-02-17 2013-12-25 F.Hoffmann-La Roche Ag A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion

Also Published As

Publication number Publication date
EP2299989A4 (en) 2013-11-13
JP5695562B2 (ja) 2015-04-08
NZ589542A (en) 2012-10-26
AU2009262871B2 (en) 2016-04-14
CA2726136A1 (en) 2009-12-30
EP2299989B1 (en) 2019-01-02
US20090299304A1 (en) 2009-12-03
CN102099020B (zh) 2013-09-18
CN102099020A (zh) 2011-06-15
EP2299989A2 (en) 2011-03-30
AU2016202212B2 (en) 2018-05-10
US20110182949A1 (en) 2011-07-28
WO2009158120A3 (en) 2010-03-04
BRPI0913214A2 (pt) 2016-01-19
AU2009262871A1 (en) 2009-12-30
AU2016202212A1 (en) 2016-05-12
JP2015083569A (ja) 2015-04-30
WO2009158120A2 (en) 2009-12-30
JP2011521974A (ja) 2011-07-28
BRPI0913214B1 (pt) 2022-05-17
US9226902B2 (en) 2016-01-05
KR101590209B1 (ko) 2016-02-01
KR20110025931A (ko) 2011-03-14
MX2010012989A (es) 2011-04-27

Similar Documents

Publication Publication Date Title
AU2016202212B2 (en) Stabilized transdermal drug delivery system
Banerjee et al. Aspect of adhesives in transdermal drug delivery systems
AU2009302853B2 (en) Amorphous rotigotine transdermal system
US7556823B2 (en) Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl
JP5591685B2 (ja) 経皮吸収製剤
EP0413487A1 (en) Method and device for administering dexmedetomidine transdermally
JP2003511425A (ja) 二元粘着性経皮薬物デリバリーシステム
EP2190392A1 (en) Transdermal drug delivery systems comprising a coated release liner
AU2006216955B2 (en) Transdermal systems having control delivery system
US20180235903A1 (en) Fentanyl Transdermal Delivery System
CN118159255A (zh) 具有柔性背衬的闭塞性贴剂
CN101304735A (zh) 用于挥发性和/或热不稳定的物质的经皮治疗体系
HK1197883A (en) Amorphous rotigotine transdermal system
HK1075816B (en) Transdermal delivery of fentanyl

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140430

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251023

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260205